









Markets
/
Stocks
/
nasdaq-tnxp
/

Tonix Pharmaceuticals Holding Corp

TNXP

28.370USD

+0.660+2.38%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

214.09MMarket Cap

LossP/E TTM



Tonix Pharmaceuticals Holding Corp

28.370

+0.660+2.38%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

126 / 175

Overall Ranking

397 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

61.667

Target Price

+127.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.09M.

Overvalued

The company’s latest PE is -0.00, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 774.96K shares, increasing 40.96% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 164.73K shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 6.37, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.00M, representing a year-over-year decrease of 9.51%, while its net profit experienced a year-over-year decrease of 64.11%.

Score

Industry at a Glance

Previous score

6.37

Change



Financials

9.78

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.23

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.12

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -0.00, which is 31.58% below the recent high of -0.00 and -3973.68% above the recent low of -0.08.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 126/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Tonix Pharmaceuticals Holding Corp is 65.00, with a high of 70.00 and a low of 50.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

61.667

Target Price

+122.54%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Tonix Pharmaceuticals Holding Corp

TNXP

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 1.10, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 36.71 and the support level at 21.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.07

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.504

Neutral

RSI(14)

39.850

Neutral

STOCH(KDJ)(9,3,3)

47.222

Neutral

ATR(14)

2.330

Low Volatility

CCI(14)

0.248

Neutral

Williams %R

61.086

Sell

TRIX(12,20)

-1.930

Sell

StochRSI(14)

23.481

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

28.480

Sell

MA10

27.335

Buy

MA20

29.991

Sell

MA50

39.356

Sell

MA100

34.847

Sell

MA200

28.404

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 9.35%, representing a quarter-over-quarter increase of 40.42%. The largest institutional shareholder is The Vanguard, holding a total of 164.73K shares, representing 1.88% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

69.58K

+17.99%

Geode Capital Management, L.L.C.

62.04K

+214.61%

The Vanguard Group, Inc.

Star Investors

91.50K

Northern Trust Investments, Inc.

13.07K

+166.86%

State Street Global Advisors (US)

20.05K

+5958.31%

CIBC Asset Management Inc.

17.57K

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 2.98, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.91. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.